---
title: "ReFRAME High-Throughput Screen Finds Repurposing Hits Active Against Toxoplasma gondii Tachyzoites"
id: "biorxiv-0-high-throughput-screen-of-advanced-repurposing-library-identifies-compounds"
canonical_url: "https://medichelpline.com/clinical-feed/biorxiv-0-high-throughput-screen-of-advanced-repurposing-library-identifies-compounds"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "bioRxiv (Biomedical Preprints)"
source_url: "https://www.biorxiv.org/content/10.64898/2026.11.13.766473v1?rss=1"
published_at: "2026-11-14T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# ReFRAME High-Throughput Screen Finds Repurposing Hits Active Against Toxoplasma gondii Tachyzoites
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/biorxiv-0-high-throughput-screen-of-advanced-repurposing-library-identifies-compounds
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** bioRxiv (Biomedical Preprints)
- **Source URL:** [Original Journal Publication](https://www.biorxiv.org/content/10.64898/2026.11.13.766473v1?rss=1)
- **Published At:** 2026-11-14T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Investigators screened the 14,095-compound **ReFRAME** repurposing library using a dual-luciferase reporter parasite to measure both active and chronic forms of infection. - The Tg68 strain was engineered to express nano luciferase driven by the pBAG1 promoter for bradyzoites and firefly luciferase driven by pTub1 for tachyzoites, permitting parallel readouts in 384-well HTS format. - Primary HTS identified 160 compounds with >80% inhibition at 10 μM against both parasite stages; cross-referencing a public HEK293T cytotoxicity dataset removed 61 compounds with CC50 20 versus HepG2) and underwent follow-up in vitro assays including tachyzoite, bradyzoite, and ex vivo cyst testing. - **Marizomib**, **monensin**, **narasin**, and **LY2090314** produced the strongest inhibition of intact cysts after 24-hour exposure in the reported assays. - When combined with clinical anti-Toxoplasma agents atovaquone and pyrimethamine, the top hits produced predominantly additive effects in the tested conditions. - Minimum inoculum of resistance (MIR) assays showed six of nine compounds yielded no detectable parasites over 30 days; LY2090314-selected populations displayed 26–29-fold resistance and carried a TgGSK3 L53V mutation. - The preprint authors reported these compounds as starting points for mechanistic work and in vivo efficacy and host-toxicity evaluation; the source did not report in vivo data or detailed dosing regimens. - This work is reported as a preprint and has not been peer reviewed, and the authors declared no competing interests.
## Clinical Analysis & Structured Key Points
[Skip to main content](https://www.biorxiv.org/content/10.64898/2026.11.13.766473v1?rss=1#main-content) [![bioRxiv](https://www.biorxiv.org/sites/default/files/biorxiv_article_logo.jpg)](https://www.biorxiv.org/) * [Home](https://www.biorxiv.org/) * [Submit](https://www.biorxiv.org/submit-a-manuscript) * [FAQ](https://www.biorxiv.org/about/FAQ) * [Blog](https://connect.biorxiv.org/news/) * [ALERTS / RSS](https://www.biorxiv.org/content/alertsrss) * [Resources](https://connect.biorxiv.org/resources/) * [About](https://www.biorxiv.org/content/about-biorxiv) * [Channels](https://www.biorxiv.org/content/10.64898/2026.11.13.766473v1?rss=1) * [4D Nucleome](https://connect.biorxiv.org/relate/content/66) * [Academia Sinica](https://connect.biorxiv.org/group/content/38) * [Advances in Genome Biology and Technology (AGBT) General Meeting 2016 #AGBT16](https://connect.biorxiv.org/relate/content/10) * [Albert Einstein College of Medicine](https://connect.biorxiv.org/group/content/4) * [Aligning Science Across Parkinson's (ASAP)](https://connect.biorxiv.org/relate/content/195) * [Allen Institute for Cell Science](https://connect.biorxiv.org/relate/content/71) * [Arc Institute](https://connect.biorxiv.org/relate/content/224) * [Babraham Institute](https://connect.biorxiv.org/relate/content/197) * [BICCN/BICAN](https://connect.biorxiv.org/relate/content/208) * [BioImaging North America](https://connect.biorxiv.org/relate/content/194) * [Biology of Genomes 2016 #BOG16](https://connect.biorxiv.org/relate/content/19) * [Breakthrough Discoveries for Thriving with Bipolar Disorder](https://connect.biorxiv.org/relate/content/236) * [Brown University](https://connect.biorxiv.org/group/content/9) * [California Institute of Technology](https://connect.biorxiv.org/group/content/32) * [Carnegie Mellon University](https://connect.biorxiv.org/group/content/19) * [Case Western Reserve University](https://connect.biorxiv.org/group/content/36) * [Central Oxford Structural Microscopy and Imaging](https://connect.biorxiv.org/relate/content/143) * [Centre for Microbiology and Environmental Systems Science](https://connect.biorxiv.org/relate/content/190) * [Chan Zuckerberg Biohub](https://connect.biorxiv.org/relate/content/121) * [Columbia University](https://connect.biorxiv.org/group/content/27) * [Donders Institute for Brain, Cognition and Behaviour](https://connect.biorxiv.org/relate/content/184) * [DREAM](https://connect.biorxiv.org/relate/content/153) * [Drug Development and Clinical Therapeutics](https://connect.biorxiv.org/relate/content/52) * [ENCODE](https://connect.biorxiv.org/relate/content/177) * [Ernst Strüngmann Institute (ESI) for Neuroscience](https://connect.biorxiv.org/relate/content/211) * [European Molecular Biology Laboratory (EMBL)](https://connect.biorxiv.org/relate/content/159) * [Francis Crick Institute](https://connect.biorxiv.org/relate/content/88) * [Fred Hutchinson Cancer Center](https://connect.biorxiv.org/group/content/28) * [Georgia Institute of Technology](https://connect.biorxiv.org/group/content/20) * [Harvard Program in Therapeutic Sciences](https://connect.biorxiv.org/relate/content/151) * [The Howard Hughes Medical Institute (HHMI)](https://connect.biorxiv.org/relate/content/227) * [Human Cell Atlas](https://connect.biorxiv.org/relate/content/163) * [Human Pangenome Reference Consortium (HPRC)](https://connect.biorxiv.org/relate/content/215) * [IMO Workshop](https://connect.biorxiv.org/relate/content/8) * [Impact of Genomic Variation on Function (IGVF)](https://connect.biorxiv.org/relate/content/214) * [Institut Pasteur](https://connect.biorxiv.org/relate/content/235/channel) * [Institute of Science and Technology Austria](https://connect.biorxiv.org/group/content/12) * [International Human Epigenome Consortium (IHEC)](https://connect.biorxiv.org/relate/content/219) * [International Mouse Phenotyping Consortium (IMPC)](https://connect.biorxiv.org/relate/content/185) * [Iowa State University](https://connect.biorxiv.org/group/content/6) * [Johns Hopkins University](https://connect.biorxiv.org/group/content/47) * [Mathematical Oncology](https://connect.biorxiv.org/relate/content/1) * [Micron Oxford](https://connect.biorxiv.org/relate/content/116) * [Michigan State University](https://connect.biorxiv.org/group/content/7) * [Morgridge Institute](https://connect.biorxiv.org/group/content/57) * [National Taiwan University](https://connect.biorxiv.org/group/content/39) * [NCI Cancer Systems Biology Consortium](https://connect.biorxiv.org/relate/content/210) * [NF Open Science Initiative](https://connect.biorxiv.org/relate/content/213) * [NCI Human Tumor Atlas Network](https://connect.biorxiv.org/relate/content/171) * [Neuromatch Conference](https://connect.biorxiv.org/relate/content/209) * [NeurotechEU](https://connect.biorxiv.org/relate/content/189) * [North Carolina State University](https://connect.biorxiv.org/group/content/37) * [Northeastern University](https://connect.biorxiv.org/group/content/54) * [Oregon Health & Sciences University](https://connect.biorxiv.org/group/content/22) * [RNA Therapeutics Institute at UMass Chan Med School](https://connect.biorxiv.org/relate/content/243) * [Rosetta Commons](https://connect.biorxiv.org/relate/content/191) * [Rutgers University](https://connect.biorxiv.org/group/content/31) * [SeroNet](https://connect.biorxiv.org/relate/content/192) * [Simons Foundation Autism Research Initiative (SFARI)](https://connect.biorxiv.org/relate/content/74) * [Society for Molecular Biology and Evolution #SMBE2016](https://connect.biorxiv.org/relate/content/29) * [Somatic Cell Genome Editing Program](https://connect.biorxiv.org/relate/content/167) * [Somatic Mosaicism across the Human Tissues Network](https://connect.biorxiv.org/relate/content/222) * [SPARC](https://connect.biorxiv.org/relate/content/187) * [Stowers Institute for Medical Research](https://connect.biorxiv.org/group/content/3) * [Stockholm University](https://connect.biorxiv.org/group/content/14) * [Tel Aviv University](https://connect.biorxiv.org/group/content/8) * [The Michael J. Fox Foundation](https://connect.biorxiv.org/relate/content/207) * [The Rockefeller University](https://connect.biorxiv.org/group/content/2) * [The Sainsbury Laboratory](https://connect.biorxiv.org/relate/content/98) * [The Whitehead Institute](https://connect.biorxiv.org/relate/content/212) * [University of Connecticut Health Center](https://connect.biorxiv.org/group/content/16) * [University of California, Berkeley](https://connect.biorxiv.org/group/content/13) * [University of California, San Diego](https://connect.biorxiv.org/group/content/41) * [University of California, San Francisco](https://connect.biorxiv.org/group/content/10) * [University of Chicago](https://connect.biorxiv.org/group/content/42) * [University of Geneva](https://connect.biorxiv.org/group/content/26) * [University of Guelph](https://connect.biorxiv.org/group/content/23) * [University of Hong Kong](https://connect.biorxiv.org/group/content/29) * [University of Illinois Chicago](https://connect.biorxiv.org/group/content/43) * [University of Iowa](https://connect.biorxiv.org/group/content/24) * [University of Kansas](https://connect.biorxiv.org/group/content/33) * [University of Massachusetts Chan Medical School](https://connect.biorxiv.org/group/content/44) * [University of New South Wales](https://connect.biorxiv.org/group/content/25) * [University of Ottawa](https://connect.biorxiv.org/group/content/35) * [University of Sydney](https://connect.biorxiv.org/group/content/50) * [Vanderbilt University](https://connect.biorxiv.org/group/content/30) * [Vienna BioCenter](https://connect.biorxiv.org/relate/content/186) * [Washington University in St. Louis](https://connect.biorxiv.org/group/content/11) * [Weizmann Institute of Science](https://connect.biorxiv.org/group/content/15) * [Yale University](https://connect.biorxiv.org/group/content/53) Search for this keyword [Advanced Search](https://www.biorxiv.org/search) ## Error message * _Notice_ : Undefined index: variant in _biorxiv_urls_url_inbound_alter()_ (line _89_ of _/opt/sites/jnl-biorxiv/site-repo/releases/20261115024317/modules/biorxiv_urls/biorxiv_urls.module_). * _Notice_ : Undefined variable: nid in _highwire_log()_ (line _330_ of _/opt/sites/jnl-biorxiv/drupal-highwire/releases/20261115024805/modules/highwire/highwire_log/highwire_log.module_). * _Notice_ : Use of undefined constant OPENSSL_RAW_DATA - assumed 'OPENSSL_RAW_DATA' in _panels_ajax_pane_encrypt_data()_ (line _44_ of _/opt/sites/jnl-biorxiv/drupal-webroot/releases/20261115024821/sites/all/modules/contrib/panels_ajax_pane/panels_ajax_pane.crypto.inc_). * _Notice_ : Undefined index: citation_manager_wrapper in _theme_highwire_article_citation()_ (line _46_ of _/opt/sites/jnl-biorxiv/drupal-highwire/releases/20261115024805/modules/highwire/highwire.include.article-citation.inc_). * _Notice_ : Undefined index: citation_manager_wrapper in _theme_highwire_article_citation()_ (line _46_ of _/opt/sites/jnl-biorxiv/drupal-highwire/releases/20261115024805/modules/highwire/highwire.include.article-citation.inc_). New Results Follow this preprint # High-Throughput Screen of Advanced Repurposing Library Identifies Compounds Active Against Acute and Chronic Stages of Toxoplasma gondii Taher Uddin, Case W McNamara, Arnab K Chatterjee, L. David Sibley doi: https://doi.org/10.64898/2026.11.13.766473 This article is a preprint and has not been certified by peer review [[what does this mean?](https://www.biorxiv.org/about/FAQ#unrefereed)]. Taher Uddin 1 Washington University in St. Louis; * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Taher%2BUddin%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Uddin%20T&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3ATaher%2BUddin%2B) Case W McNamara 2 Calibr: California Institute for Biomedical Research; * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Case%2B%2BW%2BMcNamara%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=McNamara%20C&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3ACase%2B%2BW%2BMcNamara%2B) Arnab K Chatterjee 3 Calibr-Skaggs Institute for Innovative Medicines; * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Arnab%2BK%2BChatterjee%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Chatterjee%20AK&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AArnab%2BK%2BChatterjee%2B) L. David Sibley 4 Washington Univ. Sch. Med. * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=L.%2BDavid%2BSibley%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Sibley%20LD&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AL.%2BDavid%2BSibley%2B) * For correspondence: sibley@wustl.edu * [Abstract](https://www.biorxiv.org/content/10.64898/2026.11.13.766473v1)[](https://www.biorxiv.org/panels_ajax_tab/biorxiv_tab_art/node:5964024/1) * [Info/History](https://www.biorxiv.org/content/10.64898/2026.11.13.766473v1.article-info)[](https://www.biorxiv.org/panels_ajax_tab/biorxiv_tab_info/node:5964024/1) * [Metrics](https://www.biorxiv.org/content/10.64898/2026.11.13.766473v1.article-metrics)[](https://www.biorxiv.org/panels_ajax_tab/article_tab_metrics/node:5964024/1) * [Supplementary material](https://www.biorxiv.org/content/10.64898/2026.11.13.766473v1.supplementary-material)[](https://www.biorxiv.org/panels_ajax_tab/biorxiv_tab_data/node:5964024/1) * [ Preview PDF](https://www.biorxiv.org/content/10.64898/2026.11.13.766473v1.full.pdf+html)[](https://www.biorxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:5964024/1) ![Loading](https://www.biorxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Toxoplasma gondii, a pathogen with a global burden impacting millions, has the capability to interconvert between the actively replicating tachyzoite form into a semidormant bradyzoite for, complicating treatment. Here, we utilized an advanced high throughput screen (HTS) to identify repurposing candidates from the ReFRAME library, which consolidates 14,095 molecules from three major databases, including FDA approved and late-stage clinical leads. To facilitate screening, the permissive cyst-forming Tg68 strain was genetically engineered to express nano luciferase under the pBAG1 promoter to track bradyzoite growth, and firefly luciferase under the pTub1 promoter to monitor tachyzoite growth. HTS in 384 well format identified 160 compounds that exhibited > 80% inhibition at 10 micromolar of both tachyzoites and bradyzoites. By cross referencing against a publicly available HEK293T cytotoxicity dataset, we filtered out 61 compounds based on half-maximal cytotoxicity (CC50) less 20) against HepG2. The top hits were profiled using in vitro growth assays for tachyzoites, bradyzoites, and ex vivo liberated and intact cysts. Marizomib, monensin, narasin, and LY2090314 showed the strongest inhibition following 24 h treatment of intact cysts. When tested in combination with clinical compounds atovaquone and pyrimethamine, the top hits were predominantly additive. Additionally, they were evaluated for their potential for developing resistance using a minimum inoculum of resistance (MIR) assay. Six of nine compounds tested in MIR assays yielded no detectable parasites over 30 days. In contrast, LY2090314 resistant populations exhibited 26 to 29-fold resistance and carried a TgGSK3 L53V mutation, identifying a candidate resistance determinant. Collectively, our findings identify compounds with activity against tachyzoites and bradyzoites and with low propensity for resistance, as starting points for mechanistic investigation and further evaluation of in vivo efficacy and host-toxicity liabilities. ### Competing Interest Statement The authors have declared no competing interest. ## Funder Information Declared National Institute of Allergy and Infectious Diseases, AI143857 Copyright The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.biorxiv.org/content/10.64898/2026.11.13.766473v1?rss=1#page) [ Previous](https://www.biorxiv.org/content/10.64898/2026.11.13.766375v1 "H9N2 avian influenza virus in Bangladesh: three genetically distinct co-circulating subgroups retain a largely conserved antigenic phenotype")[Next ](https://www.biorxiv.org/content/10.64898/2026.11.13.766378v1 "Optimizing Avian Influenza Viral RNA Enrichment from Water: A Comparison of Concentration Methods for Low-Volume Samples") Posted November 14, 2026. [ Download PDF](https://www.biorxiv.org/content/10.64898/2026.11.13.766473v1.full.pdf) Print/Save Options [Download PDF](https://www.biorxiv.org/content/biorxiv/early/2026/11/14/2026.11.13.766473.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.biorxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [Supplementary Material ](https://www.biorxiv.org/content/10.64898/2026.11.13.766473v1.supplementary-material) [ Email](https://www.biorxiv.org/ "Email this Article") [ Share](https://www.biorxiv.org/) High-Throughput Screen of Advanced Repurposing Library Identifies Compounds Active Against Acute and Chronic Stages of Toxoplasma gondii Taher Uddin, Case W McNamara, Arnab K Chatterjee, L. David Sibley bioRxiv 2026.11.13.766473; doi: https://doi.org/10.64898/2026.11.13.766473 This article is a preprint and has not been certified by peer review [[what does this mean?](https://www.biorxiv.org/about/FAQ#unrefereed)]. Share This Article: Copy [![Twitter logo](https://www.biorxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.biorxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.biorxiv.org%2Fcontent%2F10.64898%2F2026.11.13.766473v1%26text%3DHigh-Throughput%2520Screen%2520of%2520Advanced%2520Repurposing%2520Library%2520Identifies%2520Compounds%2520Active%2520Against%2520Acute%2520and%2520Chronic%2520Stages%2520of%2520Toxoplasma%2520gondii "Share this on Twitter") [![Facebook logo](https://www.biorxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.biorxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.biorxiv.org%2Fcontent%2F10.64898%2F2026.11.13.766473v1%26t%3DHigh-Throughput%2520Screen%2520of%2520Advanced%2520Repurposing%2520Library%2520Identifies%2520Compounds%2520Active%2520Against%2520Acute%2520and%2520Chronic%2520Stages%2520of%2520Toxoplasma%2520gondii "Share on Facebook") [![LinkedIn logo](https://www.biorxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.biorxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.biorxiv.org%2Fcontent%2F10.64898%2F2026.11.13.766473v1%26title%3DHigh-Throughput%2520Screen%2520of%2520Advanced%2520Repurposing%2520Library%2520Identifies%2520Compounds%2520Active%2520Against%2520Acute%2520and%2520Chronic%2520Stages%2520of%2520Toxoplasma%2520gondii%26summary%3D%26source%3DbioRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.biorxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.biorxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.biorxiv.org%2Fcontent%2F10.64898%2F2026.11.13.766473v1%26title%3DHigh-Throughput%2520Screen%2520of%2520Advanced%2520Repurposing%2520Library%2520Identifies%2520Compounds%2520Active%2520Against%2520Acute%2520and%2520Chronic%2520Stages%2520of%2520Toxoplasma%2520gondii "Share on Mendeley") [ Citation Tools](https://www.biorxiv.org/ "Citation Tools") [ Get QR code](https://connect.biorxiv.org/qr/2026.11.13.766473) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.biorxiv.org/content/10.64898/2026.11.13.766473v1&count=horizontal&via=&text=High-Throu
## Related Clinical Research

- [Canine TMPRSS4 in MDCK sublines enables trypsin-independent influenza A virus replication](https://medichelpline.com/clinical-feed/biorxiv-2-endogenous-serine-proteases-in-mdck-sublines-support-trypsin-independent.md)
- [Optimizing AIV RNA Recovery from 40‑mL Water Samples: AC/PEG vs EM](https://medichelpline.com/clinical-feed/biorxiv-1-optimizing-avian-influenza-viral-rna-enrichment-from-water-a-comparison-of.md)
- [FDA approves Moderna’s mRNA flu vaccine mFLUSIVA for adults 50+: what clinicians should know](https://medichelpline.com/clinical-feed/medical-news-today-0-moderna-s-mrna-flu-vaccine-approved-by-fda-when-is-it-available.md)
- [MMR vaccines: separating measles, mumps, rubella shots — myths and facts](https://medichelpline.com/clinical-feed/medical-news-today-0-should-the-measles-mumps-rubella-vaccines-be-separate-myths-vs-facts.md)
- [Influenza and Coronavirus: Comparative Evolution, Epidemiology, Antivirals, and Vaccines](https://medichelpline.com/clinical-feed/pubmed-43058094.md) (DOI: 10.1038/s41392-026-03078-5)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.